Semin Arthritis Rheu: Death rate from psoriasis arthritis

Studies on psoriasis arthritis (PsA) mortality were inconsistentThe purpose of this study is to: 1) estimate the trend of mortality in PsA patients over time, 2) assess the mortality rate of specific causes in PsA patients compared to the general population, and 3) determine the predictors of PsA mortalitythe study was conducted at the Psoriasis Arthritis Clinic in Toronto and followed patients with a prospective follow-up 6-12 months interval satiating under the standard protocolStandardized mortality (SMRs) for overall, age and gender," according to the Ontario populationThe cause of death is recorded through ICD9 and ICD10 codes and SMRs for specific causes are calculatedUsing the Cox regression model, the predictors of PsA patient mortality were determinedfollowed 1,562.8 patients in 1,490 patients - 225 (15%) were confirmed dead (111 females, 114 men)The overall SMR is 0.92 (95% CI: 0.81-1.05), the gender-specific SMRs are: 1.08 (95% CI: 0.89-1.30), and men 0.81 (95% CI: 0.66-0.97)Age-specific SMRs aged 20-39, 40-59, 60-79 and over 80 years were 3.36 (95% CI: 1.61-6.18), 0.97 (9 5% CI: 0.68-1.34), 0.88 (95% CI: 0.73-1.06) and 0.86 (95% CI:0.66-1.11)The leading causes of death include malignant neoplasms (n-61; SMR.97, 95% CI: 0.72-1.28), acute myocardial infarction (n-32; SMR is 1.11, 95% CI: 0.74-1.58) and pneumonia (n-14; SMR-2.46,95% CI:1.27-4.31)Factors found to be associated with increased mortality include elevated acute stage responders, the presence of comorbidities (such as heart disease and cancer) and low levels of educationan increased risk of death in young PsA patientsBetter control of comorbidities can reduce this risk